Breast Cancer Radiation Therapy Unit Sheba Medical Center Ramat Gan Israel

Breast Cancer Screening and Diagnostic Centre Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Breast Center Hirslanden Clinic St Anna 6006 Lucerne Switzerland

Breast Imaging Service Department of Radiology Memorial Sloan Kettering Cancer Center New York NY USA

Department of Radiation Oncology GROW School for Oncology and Developmental Biology Maastricht University Medical Centre Maastricht the Netherlands

Faculty of Health Sciences and Medicine University of Lucerne Lucerne Switzerland

Sackler School of Medicine Tel Aviv University Tel Aviv Israel

Zobrazit více v PubMed

Banys-Paluchowski M, Rubio IT, Ditsch N, Krug D, Gentilini OD, Kühn T (2023) Real de-escalation or escalation in disguise? Breast 69:249–257 PubMed DOI PMC

Gentilini OD, Botteri E, Sangalli C et al (2023) Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial. JAMA Oncol 9(11):1557–1564

Samiei S, Simons JM, Engelen SME et al (2021) Axillary pathologic complete response after neoadjuvant systemic therapy by breast cancer subtype in patients with initially clinically node-positive disease: a systematic review and meta-analysis. JAMA Surg 156(6):e210891 PubMed DOI PMC

Kaidar-Person O, Pfob A, Gentilini O et al (2023) The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus. EClinicalMedicine 61:102085 PubMed DOI PMC

Dubsky P, Pinker K, Cardoso F et al (2021) Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncol 22(1):e18–e28 PubMed DOI

Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K (2020) Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools. Oncologist 25(2):e231–e242 PubMed DOI

Farrell TP, Adams NC, Stenson M et al (2015) The Z0011 Trial: is this the end of axillary ultrasound in the pre-operative assessment of breast cancer patients? Eur Radiol 25(9):2682–2687 PubMed DOI

Samiei S, de Mooij CM, Lobbes MBI, Keymeulen KBMI, van Nijnatten TJA, Smidt ML (2021) Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 273(4):694–700 PubMed DOI

Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817–1828 PubMed DOI

Johnston SRD, Toi M, O’Shaughnessy J et al (2023) Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 24(1):77–90 PubMed DOI